MarketsandMarkets

Biomarker and Companion Diagnostics Virtual Conference (EST TIME ZONE)

20th - 23rd October 2020

Leveraging next gen technologies beyond conventional biomarker drug discovery

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

The Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 20-23 October 2020 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.

This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

WHAT TO EXPECT

  • Commercialization of CDx
  • Proteomics and Genomics based Biomarkers
  • Biomarker Drug Discovery and Assay Development
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery
  • Immuno-oncology/Neuroscience Drug Discovery
  • Diagnostic Biomarkers development
  • Personalized Medicine
  • Immunology Biomarkers

CONFERENCE AGENDA

Online Registration

10:30 - 10:50

Welcome note from MarketsandMarkets

10:50 - 10:55

Opening Remarks from the Chairman

George Pell

George Pell, CEO and Founder, Thirty-Six

10:55 - 11:00

Keynote Presentation: Vignettes of Innovative Safety Biomarker Applications to Drug Development

Shashi Ramaiah

Shashi Ramaiah, Head, Safety Biomarkers, Translational Sciences, Pfizer

11:00 - 11:30

BIOMARKERS IN CLINICAL & TRANSLATIONAL DEVELOPMENT: DRUG DISCOVERY AND ASSAY DEVELOPMENT

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

11:30 - 12:00

Paving the way for exosome-based companion diagnostics (CDx)

12:00 - 12:30

FirePlex® multiplexed assay platform - A Biomarker Discovery Tool

Zev Gechtman

Zev Gechtman , Ph.D. Technical Product Manager, Abcam

12:30 - 13:00

Networking and One-on-One Meetings on the event portal

13:00 - 13:15

Non-invasive Biomarker Discovery and Clinical Investigation Using Breath Biopsy®

Marc van der Schee

Marc van der Schee, Head, Clinical and Translational Science, Owlstone Medical Ltd

13:15 - 13:44

Advanced phenotyping in liquid and tissue biopsy: from circulating tumor cell biomarkers to highly multiplexed whole-slide imaging with the Orion™ spatial biology platform

Eric Kaldjian

Eric Kaldjian, Chief Medical Officer , RareCyte, USA

13:45 - 14:15

Clinical biomarker development for an intratumoral TLR7 agonist

 Nadia Hassounah

Nadia Hassounah, Principal Scientist, Novartis

14:15 - 14:45

Genomic and epigenomic markers to subphenotype sarcoidosis

 Nancy Casanova

Nancy Casanova, Professor, University of Arizona

14:45 - 15:15

Closing Remarks from the Chairman

15:15 - 15:20

Online Registration

10:30 - 10:50

Welcome note from MarketsandMarkets

10:50 - 10:55

Opening Remarks from the Chairman

Mike Baratta

Mike Baratta, Scientific Director, Translational Biomarker Research , Takeda

10:55 - 11:00

Keynote Presentation: Precision Medicine Tools and Immuno-Oncology

Roy Baynes

Roy Baynes, Executive Vice President, Chief Medical Officer, Eikon Therapeutics

11:00 - 11:30

INNOVATIONS IN BIOMARKER RESEARCH: DIGITAL BIOMARKERS, PRECISION MEDICINE AND BIG DATA

Applying Big-Data and Mathematical Modeling to Biomarker Discovery

 Parag Mallick

Parag Mallick, Associate Professor, Radiology, Stanford University

11:30 - 12:00

Eutropics’ Praedicare DxTM platform’s predictive functional biomarkers for liquid and solid cancer

Michael Cardone

Michael Cardone, CEO , Eutropics Pharmaceuticals Inc.

12:00 - 12:30

Mechanism of Immune Checkpoint Therapy: new data

Adil Daud

Adil Daud, Director, Melanoma Program, UCSF Medical Center

12:30 - 13:00

Networking and One-on-One Meetings on the event portal

13:00 - 13:15

Automated high-parameter FACS data analysis effectively and efficiently identifies impactful pharmacodynamic biomarkers

 Michelle Graham

Michelle Graham, Principal Scientist, Translational Medicine and Biomarkers, AbbVie

13:15 - 13:45

Multi-purpose approach to biomarker development: Diagnostic, Prognostic, Safety and Response biomarkers

Tanja Zabka

Tanja Zabka, Principal Scientist, Pathologist, Genentech

13:45 - 14:15

Biology-Inspired Intelligence | precision and personalized medicine for the brain and mind

George Pell

George Pell, CEO and Founder, Thirty-Six

14:15 - 14:45

Closing remarks from the Chairman

14:45 - 14:50

Networking and One-on-One Meetings

14:50 - 16:00

Online Registration

10:30 - 10:50

Welcome note from MarketsandMarkets

10:50 - 10:55

Opening Remarks from the Chairman

George Pell

George Pell, CEO and Founder, Thirty-Six

10:55 - 11:00

Keynote Presentation: The common thread running through CNS biomarkers - implications on new drug development

Kevin Wang

Kevin Wang, Director, Program for Neuroproteomics and Biomarkers Research, University of Florida

11:00 - 11:30

IDENTIFICATION OF RIGHT BIOMARKERS & DESIGN OF CLINICAL TRIALS IN CDX

Why is monitoring predictive biomarker data so difficult for big pharma?

Mark Gramling, PhD

Mark Gramling, PhD, Director, Oncology, Larvol

11:30 - 12:00

Thoughts on Mass Spec-Based Utility of Post-Translational Modification Tools in Clinical Development

Mike Baratta

Mike Baratta, Scientific Director, Translational Biomarker Research , Takeda

12:00 - 12:30

Targeting chromatin remodeling for cancer therapy

Shamim Mollah

Shamim Mollah, Assistant Professor, Department of Genetics, Washington University School of Medicine

12:30 - 13:00

Networking and One-on-One Meetings on the event portal

13:00 - 13:15

Unravel the molecular mechanisms of non-coding genetic variants in Alzheimer’s Disease using a scalable high-throughput pipeline

Yuk Yee Leung

Yuk Yee Leung, Assistant Professor, Pathology and Laboratory Medicine, University of Pennsylvania

13:15 - 13:45

Role of Human Biospecimens in Biomarker Research

Olga Potapova

Olga Potapova , CEO, Scientific Director, Cureline

13:45 - 14:15

Biomarker Identification, Selection, and Development

 Xinyin Lai

Xinyin Lai, Senior Research Scientist, Eli Lilly

14:15 - 14:45

Leveraging biomarker discovery through disease-perturbed network evaluation

 Dhiman Ghosh

Dhiman Ghosh, Scientist, DMPK, Takeda

14:45 - 15:15

Closing Remarks from the Chairman

15:15 - 15:20

Networking and One-on-One Meetings

15:20 - 16:00

Online Registration

10:30 - 10:50

Welcome note from MarketsandMarkets

10:50 - 10:55

Opening Remarks from the Chairman

George Pell

George Pell, CEO and Founder, Thirty-Six

10:55 - 11:00

Keynote Presentation: Biomarkers Associated With Clinical Outcomes To Anti-CD19 CAR T Cell Therapy In NHL

John Rossi

John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences

11:00 - 11:30

CDX COMMERCIALIZATION, REGULATORY UPDATES, STATISTICS & DATA IN CDX

CDx Launch Success: From Early Biomarker Development to Commercialization

Morten Frost

Morten Frost , Associate Vice President, Head, Global Marketing , Agilent, Denmark

11:30 - 12:00

Launching a Companion Diagnostic (CDx): Research and Development Through Commercialization

Scott Reid

Scott Reid, Vice President, Alliances & CDx., Neogenomics

12:00 - 12:30

Challenges of getting Trial/Study approval and NGS CDx commercial launch in China

Tom Li

Tom Li, Head of US Biopharma BD, Burning Rock Dx

12:30 - 13:00

Global companion diagnostic commercialization: Day-One matters

Dr. Reinhard Ortmann

Dr. Reinhard Ortmann, Director Oncology & Precision Diagnostics, QIAGEN, Germany

13:00 - 13:30

Closing remarks from the Chairman

13:30 - 13:35

Networking and One-on-One Meetings

13:35 - 15:00

End of Conference

15:00 - 15:00

SPEAKERS

John Rossi

John Rossi

Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Mike Baratta

Mike Baratta

Scientific Director, Translational Biomarker Research , Takeda

Pallavi Sachdev

Pallavi Sachdev

Senior Director, Clinical Pharmacology and Translational Medicine, Eisai

Adil Daud

Adil Daud

Director, Melanoma Program, UCSF Medical Center

Kevin Wang

Kevin Wang

Director, Program for Neuroproteomics and Biomarkers Research, University of Florida

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

George Pell

George Pell

CEO and Founder, Thirty-Six

Eric Kaldjian

Eric Kaldjian

Chief Medical Officer , RareCyte, USA

 Xinyin Lai

Xinyin Lai

Senior Research Scientist, Eli Lilly

Shamim Mollah

Shamim Mollah

Assistant Professor, Department of Genetics, Washington University School of Medicine

Yuk Yee Leung

Yuk Yee Leung

Assistant Professor, Pathology and Laboratory Medicine, University of Pennsylvania

 Parag Mallick

Parag Mallick

Associate Professor, Radiology, Stanford University

Tanja Zabka

Tanja Zabka

Principal Scientist, Pathologist, Genentech

 Nancy Casanova

Nancy Casanova

Professor, University of Arizona

 Michelle Graham

Michelle Graham

Principal Scientist, Translational Medicine and Biomarkers, AbbVie

Shashi Ramaiah

Shashi Ramaiah

Head, Safety Biomarkers, Translational Sciences, Pfizer

Martin Schlumpberger

Martin Schlumpberger

Director, Product Development, Qiagen

Scott Reid

Scott Reid

Vice President, Alliances & CDx., Neogenomics

Zev Gechtman

Zev Gechtman

Ph.D. Technical Product Manager, Abcam

 Dhiman Ghosh

Dhiman Ghosh

Scientist, DMPK, Takeda

Tom Li

Tom Li

Head of US Biopharma BD, Burning Rock Dx

 Nadia Hassounah

Nadia Hassounah

Principal Scientist, Novartis

Marc van der Schee

Marc van der Schee

Head, Clinical and Translational Science, Owlstone Medical Ltd

Mark Gramling, PhD

Mark Gramling, PhD

Director, Oncology, Larvol

Dr. Reinhard Ortmann

Dr. Reinhard Ortmann

Director Oncology & Precision Diagnostics, QIAGEN, Germany

Michael Cardone

Michael Cardone

CEO , Eutropics Pharmaceuticals Inc.

Morten Frost

Morten Frost

Associate Vice President, Head, Global Marketing , Agilent, Denmark

Olga Potapova

Olga Potapova

CEO, Scientific Director, Cureline

Michael Valentino

Michael Valentino

Scientific Director of Companion Diagnostics, Exosome Diagnostics, A Bio-Techne Brand

SPONSORS